Biodistribution and radiation dosimetry of the novel hypoxia PET probe [¹⁸F]DiFA and comparison with [¹⁸F]FMISO.

ABSTRACT:

Background

To facilitate hypoxia imaging in a clinical setting, we developed 1-(2,2-dihydroxymethyl-3-[¹⁸F]-fluoropropyl)-2-nitroimidazole ([¹⁸F]DiFA) as a new tracer that targets tumor hypoxia with its lower lipophilicity and efficient radiosynthesis. Here, we evaluated the radiation dosage, biodistribution, human safety, tolerability, and early elimination after the injection of [¹⁸F]DiFA in healthy subjects, and we performed a preliminary clinical study of patients with malignant tumors in a comparison with [¹⁸F]fluoromisonidazole ([¹⁸F]FMISO).

Results

The single administration of [¹⁸F]DiFA in 8 healthy male adults caused neither adverse events nor abnormal clinical findings. Dynamic and sequential whole-bo

SUBMITTER: Watanabe S 

PROVIDER: S-EPMC6611855 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature